ALK-EML4 (Eex13Aex20)

EML4-ALK · Variant type: fusion · Fusion partner: EML4 (Eex13Aex20)

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Gilteritinib	99.8%	0.1%	88.97
2	Entrectinib	99.6%	0.4%	93.69
3	Repotrectinib	99.4%	0.6%	84.21
4	Sunitinib	84.7%	15.3%	91.73
5	Pralsetinib	81.3%	18.7%	93.43
6	Alpelisib	75.1%	24.9%	97.22
7	Pacritinib	51.2%	48.8%	88.64
8	Tenalisib	44.9%	55.1%	97.98
9	Defactinib	32.4%	67.6%	92.68
10	Lazertinib	27.6%	72.4%	97.47
11	Fedratinib	21.1%	78.9%	96.21
12	Neratinib	19.9%	80.1%	93.18
13	Tepotinib	19.7%	80.3%	99.75
14	Erdafitinib	16.6%	83.4%	95.71
15	Upadacitinib	15.0%	85.0%	97.98
16	Darovasertib	13.6%	86.4%	96.99
17	Selpercatinib	13.3%	86.7%	96.72
18	Deucravacitinib	13.1%	86.9%	98.99
19	Erlotinib	11.7%	88.3%	99.75
20	Abrocitinib	9.8%	90.2%	99.50
21	Pexidartinib	8.3%	91.7%	99.49
22	Abemaciclib	7.1%	92.9%	91.48
23	Avapritinib	6.4%	93.6%	97.73
24	Rabusertib	6.2%	93.8%	98.74
25	Pemigatinib	5.5%	94.5%	98.23

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Gilteritinib	99.8%	—	—
Entrectinib	99.6%	—	—
Repotrectinib	99.4%	—	—
Sunitinib	84.7%	—	—
Pralsetinib	81.3%	—	—
Alpelisib	75.1%	—	—
Pacritinib	51.2%	—	—
Tenalisib	44.9%	—	—
Defactinib	32.4%	—	—
Lazertinib	27.6%	—	—
Fedratinib	21.1%	—	—
Neratinib	19.9%	—	—
Tepotinib	19.7%	—	—
Erdafitinib	16.6%	—	—
Upadacitinib	15.0%	—	—
Darovasertib	13.6%	—	—
Selpercatinib	13.3%	—	—
Deucravacitinib	13.1%	—	—
Erlotinib	11.7%	—	—
Abrocitinib	9.8%	—	—
Pexidartinib	8.3%	—	—
Abemaciclib	7.1%	—	—
Avapritinib	6.4%	—	—
Rabusertib	6.2%	—	—
Pemigatinib	5.5%	—	—

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.3ms